Archives20242023202220212020201920182017201620152014201320122011 May 11, 2023FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022 Read More April 19, 2023FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus Read More April 12, 2023ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP Read More March 27, 2023Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA Read More March 07, 2023Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy Read More February 06, 2023Phase 2/3 adaptive study design for Lupus study agreed with Avion Read More January 05, 2023Major Interest | TR1 | Gary Smith Read More January 03, 2023Major Interest | TR1 | Lanstead Capital – 3 January 2023 Read More December 22, 2022Grant of Share Options Read More December 22, 2022End of Year Update Read More November 18, 2022Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities Read More September 30, 2022Lupuzor™ Update Read More 12345…21
April 19, 2023FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus Read More
April 12, 2023ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP Read More
March 27, 2023Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA Read More
March 07, 2023Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy Read More
November 18, 2022Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities Read More